Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | LTA4H | P09960 | 1/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | ABL1 | P00519 | 1/20 | 0.58 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.58 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.58 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.58 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1519223 | 0.94 | MEN1 (0.69) | MEN1TSHRKMT2ALTA4HABL1 | |
| Hydrochloric Acid SCHEMBL2551741 | 0.92 | MEN1 (0.68) | MEN1TSHRKMT2ALTA4HABL1 | |
| SCHEMBL5016390 | 0.89 | MEN1 (0.65) | MEN1TSHRKMT2AKDM4EALDH1A1 | |
| SCHEMBL18125935 | 0.88 | ALDH1A1 (0.71) | MEN1KMT2ALTA4HKDM4EALDH1A1 | |
| SCHEMBL3844177 | 0.88 | ALDH1A1 (0.71) | MEN1KMT2ALTA4HKDM4EALDH1A1 | |
| Formic Acid SCHEMBL28857498 | 0.88 | MEN1 (0.62) | MEN1TSHRKMT2ALTA4HABL1 | |
| SCHEMBL12205291 | 0.87 | ALDH1A1 (0.60) | MEN1KMT2ALTA4HKDM4EALDH1A1 | |
| SCHEMBL16291177 | 0.86 | MEN1 (0.68) | MEN1TSHRKMT2AABL1RIN1 | |
| SCHEMBL27405361 | 0.85 | MEN1 (0.60) | MEN1TSHRKMT2AKDM4EALDH1A1 | |
| SCHEMBL22483727 | 0.84 | KCNH2 (0.59) | MEN1TSHRKMT2ALTA4HS1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101605784-B | Aza-bridged-ring compound | ASTELLAS PHARMA INC JP | 2013-04-10 | — | — | CN | disclosed |
| CN-101605784-A | Aza-bridged-ring compound | ASTELLAS PHARMA INC (JP) | 2009-12-16 | — | — | CN | disclosed |
| EP-1250337-B1 | SUBSTITUTED HOMOPIPERIDINYL BENZIMIDAZOLE ANALOGUES AS FUNDIC RELAXANTS | JANSSEN PHARMACEUTICA NV (BE) | 2008-12-03 | — | — | EP | disclosed |
| US-7304052-B2 | Substituted homopiperidinyl benzimidazole analogues as fundic relaxants | JANSSEN PHARMACEUITCA N.V. (BE) | 2007-12-04 | — | — | US | disclosed |
| US-20030139393-A1 | Substituted homopiperidinyl benzimidazole analogues as fundic relaxants | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139393-A1 | Substituted homopiperidinyl benzimidazole analogues as fundic relaxants | HRH2, CBR1, HTR1D | MEN1 3118/4885TSHR 1503/4885KMT2A 1660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.